Assertio Holdings, Inc. to Report Second Quarter 2023 Financial Results on Thursday, August 3, 2023
24 juil. 2023 08h30 HE
|
Assertio Holdings, Inc.
LAKE FOREST, Ill., July 24, 2023 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a specialty pharmaceutical company offering differentiated products to...
Assertio Holdings Joins Russell 3000® Index
26 juin 2023 07h00 HE
|
Assertio Holdings, Inc.
LAKE FOREST, Ill., June 26, 2023 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a specialty pharmaceutical company, today announced that it has joined the...
Assertio Reports First Quarter 2023 Financial Results, Raises Full Year 2023 Outlook
09 mai 2023 07h15 HE
|
Assertio Holdings, Inc.
Net Product Sales Increase 18% Year-Over-Year Raises Full Year Outlook to Net Product Sales of $157 to $167 Million, Adjusted EBITDA $90 to $98 Million To Acquire Spectrum...
Assertio Holdings, Inc. Updates First Quarter 2023 Financial Results Call Time to Tuesday, May 9, 2023 at 11:30 am Eastern Time
05 mai 2023 08h00 HE
|
Assertio Holdings, Inc.
LAKE FOREST, Ill., May 05, 2023 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a specialty pharmaceutical company offering differentiated products to...
Assertio Holdings, Inc. to Report First Quarter 2023 Financial Results on Tuesday, May 9, 2023
27 avr. 2023 09h00 HE
|
Assertio Holdings, Inc.
LAKE FOREST, Ill., April 27, 2023 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a specialty pharmaceutical company offering differentiated products to...
Assertio Holdings, Inc. to Acquire Spectrum Pharmaceuticals, Inc. in All Stock and CVR Transaction
25 avr. 2023 06h00 HE
|
Assertio Holdings, Inc.; Spectrum Pharmaceuticals, Inc.
Complementary Commercial Growth Platforms Anticipated to Accelerate ROLVEDON™ (eflapegrastim-xnst) Injection Profitability and Diversify Revenue Streams Combination of Assertio’s Omni-Channel...
Assertio Provides Educational Grant for New Lennox-Gastaut Syndrome (LGS) Foundation Treatments Kits
24 avr. 2023 09h00 HE
|
Assertio Holdings, Inc.
SYMPAZAN (clobazam) oral CIV film from Assertio is used for the adjunctive treatment of seizures associated with LGS in patients two years of age and older Oral film delivery from SYMPAZAN® delivers...
Assertio Holdings, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
07 avr. 2023 16h00 HE
|
Assertio Holdings, Inc.
LAKE FOREST, Ill., April 07, 2023 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT), a specialty pharmaceutical company offering differentiated products to...
Assertio Reports Fourth Quarter and Full Year 2022 Financial Results
08 mars 2023 16h01 HE
|
Assertio Holdings, Inc.
Net Product Sales Increase 55% in the Fourth Quarter, 42% for the Full Year Full Year Net Income Increases to $109.6 Million, Non-GAAP Adjusted EBITDA Increases to $101.6 Million Cash Flows from...
Assertio Appoints Dr. Howard Franklin as Senior Vice President, Medical
06 mars 2023 09h00 HE
|
Assertio Holdings, Inc.
LAKE FOREST, Ill., March 06, 2023 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a specialty pharmaceutical company offering differentiated products to...